Japan CRO CMIC Acquires Daiichi Sankyo Shizuoka Facility
This article was originally published in PharmAsia News
Japan's largest contract research organization CMIC Nov. 30 announced an agreement to acquire a facility from Daiichi Sankyo. The 210,000-square meter facility based in Shimada, Shizuoka Prefecture manufactures antibacterial agent Cravit (levofloxacin) and hemostatic drug Transamin (tranexamic). Daiichi plans to move some of its production to other sites and keep the rest for contract manufacture for SMIC. According to the deal, SMIC plans to acquire all outstanding shares by April 2010; the two companies did not disclose further terms . (Click here for more - Japanese language
You may also be interested in...
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.